Ezetimibe and bile acid binders trials

6 studies from 1984 to 2022, with 40,669 people taking part. Results: 4 fewer heart events or deaths, 2 no clear benefit. Every summary comes from the trial's PubMed abstract.

Fewer heart events or deaths
No clear benefit
Lipid or plaque goal met
Safety, side effects or genetics

1984 to 20266 studies, 40,669 people in trials

Circle size shows how many people took part. Tap a circle to open the trial; on a phone, swipe sideways for earlier years. The people count leaves out meta-analyses and genetic studies, which pool other studies.

All 6 studies

RACING2022 · Rosuvastatin + ezetimibe · 3,780 people
In patients with atherosclerotic cardiovascular disease, moderate-intensity rosuvastatin plus ezetimibe was non-inferior to high-intensity rosuvastatin alone for 3-year cardiovascular outcomes, achieved more patients with LDL under 70 mg/dL, and caused less drug intolerance-related discontinuation or dose reduction.
No significant benefitEzetimibe and bile acid bindersUS-approved
EWTOPIA 752019 · Ezetimibe · 3,796 people
In patients aged 75 or older with elevated LDL-C and no history of coronary disease, adding ezetimibe to usual care reduced cardiovascular events, though open-label design, early termination, and follow-up issues warrant cautious interpretation of the benefit's magnitude.
BenefitEzetimibe and bile acid bindersUS-approved
IMPROVE-IT2015 · Ezetimibe + simvastatin · 18,144 people
Adding ezetimibe to statin therapy after acute coronary syndrome modestly reduces cardiovascular events beyond statin alone, with similar safety.
BenefitEzetimibe and bile acid bindersUS-approved
SHARP2011 · Simvastatin + ezetimibe · 9,270 people
In patients with moderate-to-severe chronic kidney disease, lowering LDL cholesterol with simvastatin plus ezetimibe safely reduced major atherosclerotic events compared with placebo.
BenefitEzetimibe and bile acid bindersUS-approved
SEAS2008 · Simvastatin + ezetimibe · 1,873 people
In patients with mild-to-moderate asymptomatic aortic stenosis, simvastatin plus ezetimibe did not reduce the composite of aortic-valve and ischemic cardiovascular events, though it reduced ischemic events alone and was associated with more cancer cases.
No significant benefitEzetimibe and bile acid bindersUS-approved
LRC-CPPT1984 · Cholestyramine · 3,806 people
Lowering LDL-C with cholestyramine significantly reduced coronary heart disease events in high-risk hypercholesterolemic men, though it did not significantly reduce overall mortality.
BenefitEzetimibe and bile acid bindersUS-approved

Other medicines

Search and filter all 106 studies in the trial database. Education only, not medical advice.

Get your LDL treated to a goal.

We're rolling out services slowly and taking a limited number of patients. Join the waitlist to get an early spot.

Join the Waitlist